Table 1. Patients’ baseline demographics for all patients, KRAS mutations, KRAS subgroups, TP53 mutations and KRAS/TP53 co–mutations.
| Variable | All patients (n=119) | KRASmut (n=62) | KRASwt (n=57) | P value | KRASG12C (n=32) | KRASother (n=30) | P value | TP53mut (n=56) | TP53wt (n=63) | P value | KRASG12C/TP53mut (n=12) | KRASother/TP53mut (n=14) | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y (median, range) | 68 [40–86] | 66 [45–85] | 69 [40–86] | 0.53 | 65 [53–84] | 67 [45–85] | 0.75 | 66 [40–86] | 68 [48–86] | 0.25 | 62 [53–77] | 66 [45–81] | 0.90 |
| Sex, n (%) | 0.20 | 0.22 | 0.14 | 1.0 | |||||||||
| Female | 51 (42.9) | 30 (48.4) | 21 (36.8) | 14 (43.8) | 12 (40.0) | 28 (50.0) | 23 (36.5) | 6 (50.0) | 7 (50.0) | ||||
| Male | 68 (57.8) | 32 (51.6) | 36 (63.2) | 18 (56.3) | 18 (60.0) | 28 (50.0) | 40 (63.5) | 6 (50.0) | 7 (50.0) | ||||
| ECOG–PS, n (%, 0–1 vs. ≥2) | 0.18 | 0.19 | 0.90 | 0.37 | |||||||||
| 0–1 | 92 (77.3) | 51 (82.3) | 41 (71.9) | 24 (75.0) | 27 (90.0) | 43 (76.8) | 49 (77.8) | 8 (66.7) | 12 (85.7) | ||||
| 2 | 23 (19.3) | 9 (14.5) | 14 (24.6) | 6 (18.8) | 3 (10.0) | 13 (23.2) | 10 (15.9) | 4 (33.3) | 2 (14.3) | ||||
| 3 | 4 (3.4) | 2 (3.2) | 2 (3.5) | 2 (6.3) | 0 | 0 | 4 (6.3) | 0 | 0 | ||||
| Smoking history, n (%) | 0.08 | 1.0 | 1.0 | 1.0 | |||||||||
| Current or former smoker | 98 (91.6) | 55 (96.5) | 43 (86.0) | 28 (96.6) | 27 (96.4) | 49 (92.5) | 49 (90.7) | 12 (100.0) | 14 (100.0) | ||||
| Never smoker | 9 (8.4) | 2 (3.5) | 7 (14.0) | 1 (3.4) | 1 (3.3) | 4 (7.5) | 5 (9.3) | 0 | 0 | ||||
| Missing data | 12 (–) | 5 (–) | 7 (–) | 1 (–) | 2 (–) | 3 (–) | 9 (–) | 0 | 0 | ||||
| Histology, n (%, LuAD vs. other) | 0.49 | 1.0 | 0.89 | 0.64 | |||||||||
| Adenocarcinoma (LuAD) | 95 (79.8) | 51 (82.3) | 44 (77.2) | 26 (81.3) | 25 (83.3) | 45 (80.4) | 50 (79.4) | 9 (75.0) | 12 (85.7) | ||||
| Other | 24 (20.2) | 11 (17.7) | 13 (22.8) | 6 (18.8) | 5 (16.7) | 11 (19.6) | 13 (20.6) | 3 (25.0) | 2 (14.3) | ||||
| Adenosquamous carcinoma (ASQ) | 11 (9.3) | 5 (8.0) | 6 (10.6) | 3 (9.4) | 2 (6.7) | 5 (8.9) | 6 (9.6) | 1 (8.3) | 0 | ||||
| Large cell carcinoma (LCC) | 1 (0.8) | 1 (1.6) | 0(0) | 0 | 1 (3.3) | 1 (1.8) | 0 | 1 (8.3) | 1 (7.1) | ||||
| Not otherwise specified (NOS) | 12 (10.1) | 5 (8.1) | 7 (12.3) | 3 (9.4) | 2 (6.7) | 5 (8.9) | 7 (11.1) | 1 (8.3) | 1 (7.1) | ||||
| PD–L1 expression (%TC), median (95% CI) | 75 [65–75] | 75 [65–83] | 65 [65–75] | 0.13 | 75 [55–85] | 75 [70–85] | 0.38 | 73 [65–75] | 75 [65–80] | 0.72 | 75 [60–95] | 70 [63–78] | 0.67 |
| 50–59%, n (%) | 34 (28.6) | 16 (25.8) | 18 (31.6) | 11 (34.4) | 5 (16.7) | 14 (25.0) | 20 (31.7) | 3 (25.0) | 2 (14.3) | ||||
| 60–69%, n (%) | 20 (16.8) | 8 (12.9) | 12 (21.1) | 3 (9.4) | 5 (16.7) | 13 (23.2) | 7 (11.1) | 2 (16.7) | 5 (35.7) | ||||
| 70–79%, n (%) | 23 (19.3) | 12 (19.4) | 11 (19.3) | 6 (18.8) | 6 (20.0) | 11 (19.6) | 12 (19.0) | 2 (16.7) | 3 (21.4) | ||||
| 80–89%, n (%) | 17 (14.3) | 11 (17.7) | 6 (10.5) | 4 (12.5) | 7 (23.3) | 3 (5.4) | 14 (22.2) | 0 | 1 (7.1) | ||||
| 90–100%, n (%) | 25 (21.0) | 15 (24.2) | 10 (17.5) | 8 (25.0) | 7 (23.3) | 15 (26.8) | 10 (15.9) | 5 (41.7) | 3 (21.4) | ||||
| Stage at primary diagnosis | 0.45 | 1.0 | 0.98 | 0.20 | |||||||||
| III | 19 (16.0) | 8 (12.9) | 11 (19.3) | 4 (12.5) | 4 (13.3) | 9 (16.1) | 10 (15.9) | 2 (16.7) | 0 | ||||
| IV | 100 (84.0) | 54 (87.1) | 46 (80.7) | 28 (87.5) | 26 (86.7) | 47 (83.9) | 53 (84.1) | 10 (83.3) | 14 (100.0) | ||||
| Prior treatment with curative intent, n (%) | 10 (8.4) | 4 (6.5) | 6 (10.5) | 0.52 | 1 (3.1) | 3 (10.0) | 0.35 | 5 (8.9) | 5 (7.9) | 0.85 | 0 | 1 (7.1) | 1.0 |
| Metastatic sites at the begin of IO, n (%) | |||||||||||||
| ADR | 20 (16.8) | 8 (12.9) | 12 (21.1) | 0.33 | 4 (12.5) | 4 (13.3) | 1.0 | 11 (19.6) | 9 (14.3) | 0.47 | 1 (8.3) | 2 (14.3) | 1.0 |
| BRA | 24 (20.2) | 13 (21.0) | 11 (19.3) | 0.82 | 7 (21.9) | 6 (20.0) | 1.0 | 15 (26.8) | 9 (14.3) | 0.11 | 5 (41.7) | 5 (35.7) | 1.0 |
| HEP | 12 (10.1) | 4 (6.5) | 8 (14.0) | 0.23 | 1 (3.1) | 3 (10.0) | 0.35 | 7 (12.5) | 5 (7.9) | 0.55 | 1 (8.3) | 1 (7.1) | 1.0 |
| OSS | 33 (27.7) | 17 (27.4) | 16 (28.1) | 0.94 | 9 (28.1) | 8 (26.7) | 1.0 | 15 (26.8) | 18 (28.6) | 0.84 | 4 (33.3) | 3 (21.4) | 0.67 |
*, P<0.05; CI, confidence interval; ECOG–PS, Eastern Co–operative Oncology Group Performance Status; %TC, percentage of positive tumor cells; ADR, adrenal metastases; BRA, brain metastases; HEP, liver metastases; OSS, bone metastases; KRASmut, KRAS mutation; KRASwt, KRAS wildtype; KRASother, KRAS mutation other than KRASG12C; TP53mut, TP53 mutation; TP53wt, TP53 wildtype.